IDEXX Laboratories Guides FY26 In Line With Estimates - Update

February 02, 2026 — 06:48 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - While reporting financial results for the fourth quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) initiated its earnings and revenue guidance for the full-year 2026, in line with analysts' estimates.

For fiscal 2026, the company now projects earnings in a range of $14.29 to $14.80 per share on revenues between $4.632 billion and $4.720 billion, with revenue growth of 7.6 to 9.6 percent and organic revenue growth of 7 to 9 percent.

On average, analysts polled expect the company to report earnings of $14.45 per share on revenues of $4.66 billion for the year. Analysts' estimates typically exclude special items. In Monday's pre-market trading, IDXX is trading on the Nasdaq at $669.95, down $0.51 or 0.08 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

IDEXX Laboratories Guides FY26 In Line With Estimates - Update

Tags

Latest Articles